Hematológia–Transzfuziológia
Volume/Issue:
Volume 52: Issue 2
Ibrutinibrezisztencia krónikus limfocitás leukémiában
Authors:
Dóra Aczél 1MTA–SE Lendület Molekuláris Onkohematológia Kutatócsoport, I. sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Dóra Aczél in
Current site
Google Scholar
PubMed Close
,
Zoltán Mátrai 2Országos Hematológiai és Infektológiai Intézet, Dél-pesti Centrumkórház, Budapest

Search for other papers by Zoltán Mátrai in
Current site
Google Scholar
PubMed Close
,
Richárd Kiss 1MTA–SE Lendület Molekuláris Onkohematológia Kutatócsoport, I. sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Richárd Kiss in
Current site
Google Scholar
PubMed Close
,
Alexandra Balogh 3III. sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest

Search for other papers by Alexandra Balogh in
Current site
Google Scholar
PubMed Close
,
Sarolta Illés 3III. sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest

Search for other papers by Sarolta Illés in
Current site
Google Scholar
PubMed Close
,
Csaba Bödör 1MTA–SE Lendület Molekuláris Onkohematológia Kutatócsoport, I. sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Csaba Bödör in
Current site
Google Scholar
PubMed Close
, and
Donát Alpár 1MTA–SE Lendület Molekuláris Onkohematológia Kutatócsoport, I. sz. Patológiai és Kísérleti Rákkutató Intézet, Semmelweis Egyetem, 1085 Budapest, Üllői út 26.

Search for other papers by Donát Alpár in
Current site
Google Scholar
PubMed Close
Pages:
136–148
Online Publication Date:
Jun 2019
Publication Date:
01 Jun 2019
Article Category:
Review Article
DOI:
https://doi.org/10.1556/2068.2019.52.2.8
Keywords:
CLL; ibrutinib; targeted therapy; treatment resistance; molecular monitoring;
Keywords (Hungarian):
CLL; ibrutinib; célzott kezelés; terápiás rezisztencia; molekuláris monitorozás;
Open access

Absztrakt:

A krónikus limfocitás leukémia a nyugati világban leggyakrabban előforduló felnőttkori leukémiatípus, mely heterogén klinikai lefolyással és változatos genetikai háttérrel társul. A széles körben alkalmazott kemo-immunoterápiák mellett az elmúlt években új, célzott kezeléseket biztosító kis molekulájú gyógyszerek váltak elérhetővé, mint a kinázgátló ibrutinib, acalabrutinib és idelalisib, valamint a BCL2 antagonista venetoclax. Jelenleg hazánkban a krónikus limfocitás leukémia terápiáját forradalmasító, korszerű kezelések közül az ibrutinib monoterápia nemcsak relabáló vagy refrakter betegeknél, hanem rossz prognózisú, TP53-defektust hordozó betegeknél első vonalban is alkalmazható. A látványos klinikai sikerek ellenére a betegek egy részében rezisztencia alakul ki ibrutinibkezelés mellett, melynek hátterében álló genetikai változásokhoz és molekuláris mechanizmusokhoz kapcsolódóan egyre több adat áll rendelkezésre a nemzetközi irodalomban. Közleményünkben ismertetjük a B-sejt receptor jelátviteli útvonalnak a krónikus limfocitás leukémia patogenezisében betöltött szerepét, mely egyúttal az ibrutinibkezelés célpontjaként is szolgál. Továbbá bemutatjuk az ibrutinibterápia hatásmechanizmusát és sajátosságait, valamint a kezelés során megjelenő, klinikai rezisztenciát kísérő genetikai változásokat. Végül áttekintjük a terápiás rezisztencia molekuláris módszerekkel való monitorozásának és korai kimutatásának lehetőségeit és korlátait, valamint a rezisztencia megjelenését követően alkalmazható kezelési lehetőségeket.

  • 1

    Losonczy H, Méhes G. B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Matolcsy A, Udvardy M, Kopper L. (ed.) Atlas of hematological diseases. [B–sejtes krónikus lymphocytás leukaemia/kis lymphocytás lymphoma. In: Matolcsy A, Udvardy M, Kopper L. (szerk.) Hematológiai betegségek atlasza.] Medicina Könyvkiadó Rt., Budapest, 2006; pp. 223–230. [Hungarian]

  • 2

    Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 1910–1916.

  • 3

    Brown JR. How I treat CLL patients with ibrutinib. Blood 2018; 131: 379–386.

  • 4

    Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature 2015; 526: 525–530.

  • 5

    Puente XS, Bea S, Valdes-Mas R, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature 2015; 526: 519–524.

  • 6

    Rendeiro AF, Schmidl C, Strefford JC, et al. Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nat Commun. 2016; 7: 11938.

  • 7

    Yeh YY, Ozer HG, Lehman AM, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 2015; 125: 3297–3305.

  • 8

    Oakes CC, Claus R, Gu L, et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia. Cancer Discov. 2014; 4: 348–361.

  • 9

    Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017; 8: 2185.

  • 10

    Kiss R, Alpár D, Gángó A, et al. Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. Haematologica 2019; 104: e38–e41.

  • 11

    Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017; 1: 715–727.

  • 12

    Leeksma AC, Taylor J, Wu B, et al. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia. Leukemia 2019; 33: 390–402.

  • 13

    Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018; 131: 2745–2760.

  • 14

    Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 2016; 127: 208–215.

  • 15

    Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164–1174.

  • 16

    Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018; 8: 93.

  • 17

    Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013; 369: 32–42.

  • 18

    Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015; 373: 2425–2437.

  • 19

    Farooqui MZ, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single–arm trial. Lancet Oncol. 2015; 16: 169–176.

  • 20

    Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997–1007.

  • 21

    Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP–196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374: 323–332.

  • 22

    Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374: 311–322.

  • 23

    Herman SEM, Barr PM, McAuley EM, et al. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 2013; 27: 1769.

  • 24

    Sharman J, Hawkins M, Kolibaba K, et al. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood 2015; 125: 2336–2343.

  • 25

    Jeyakumar D and O’Brien S. B cell receptor inhibition as a target for CLL therapy. Best Pract Res Clin Haematol. 2016; 29: 2–14.

  • 26

    Rowley RB, Burkhardt AL, Chao HG, et al. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem. 1995; 270: 11590–11594.

  • 27

    Packard TA, Cambier JC. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation. F1000Prime Rep. 2013; 5: 40.

  • 28

    Ransom JT, Harris LK, Cambier JC. Anti-Ig induces release of inositol 1,4,5-trisphosphate, which mediates mobilization of intracellular Ca++ stores in B lymphocytes. J Immunol. 1986; 137: 708–714.

  • 29

    Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol. 2002; 2: 945–956.

  • 30

    Seiler T, Dreyling M. Bruton’s tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives. Expert Opin Investig Drugs. 2017; 26: 909–915.

  • 31

    Cheng S, Ma J, Guo A, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 2014; 28: 649–657.

  • 32

    Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010; 107: 13075–13080.

  • 33

    Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013; 31: 88–94.

  • 34

    Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287–6296.

  • 35

    Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood 2014; 123: 3286–3295.

  • 36

    Deeks ED. Ibrutinib: A Review in chronic lymphocytic leukaemia. Drugs 2017; 77: 225–236.

  • 37

    Niemann CU, Herman SE, Maric I, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib-findings from an investigator-initiated Phase II study. Clin Cancer Res. 2016; 22: 1572–1582.

  • 38

    Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182–1189.

  • 39

    Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013; 122: 2539–2549.

  • 40

    Al-Sawaf O, Fischer K, Eichhorst B, et al. Targeted therapy of CLL. Oncol Res Treat. 2016; 39: 768–778.

  • 41

    Gurbity Pálfi T, Fésüs V, Bödör C, et al. State of the art molecular diagnostics and therapy of chronic lymphocytic leukaemia in the era of new targeted therapies. [A krónikus lymphocytás leukaemia korszerű molekuláris diagnosztikája és kezelése az új célzott terápiák korszakában.] Orv Hetil. 2017; 158: 1620–1629. [Hungarian]

  • 42

    Rafei H, Kharfan-Dabaja MA. Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. Hematol Oncol Stem Cell Ther. 2018; 11: 1–12.

  • 43

    Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117–124.

  • 44

    Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010; 28: 4473–4479.

  • 45

    Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014; 123: 3247–3254.

  • 46

    Fésüs V, Marosvári D, Kajtár B, et al. TP53 mutation analysis in chronic lymphocytic leukaemia. [A TP53-mutáció-analízis jelentősége krónikus lymphocytás leukaemiában.] Orv Hetil. 2017; 158: 220–228.

  • 47

    Malcikova J, Tausch E, Rossi D, et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia 2018; 32: 1070–1080.

  • 48

    Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446–5456.

  • 49

    Pospisilova S, Gonzalez D, Malcikova J, et al. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia. Leukemia 2012; 26: 1458–1461.

  • 50

    Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009; 114: 5307–5314.

  • 51

    Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood 2009; 114: 2589–2597.

  • 52

    Soumerai JD, Ni A, Xing G, et al. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma 2018; 8: 1–9.

  • 53

    Hu B, Patel KP, Chen HC, et al. Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019; .

    • Crossref
    • Export Citation
  • 54

    Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015; 16: 169–176.

  • 55

    Langerbeins P, Bahlo J, Rhein C, et al. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol. 2015; 11: 1895–1903.

  • 56

    Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood 2018; 131: 2357–2366.

  • 57

    Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213–223.

  • 58

    Brown JR, Hillmen P, O’Brien S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL. Leukemia 2017; 32: 83.

  • 59

    Byrd JC, Hillmen P, O’Brien S, et al. Long-term follow-up of the RESONATE™ phase 3 trial of ibrutinib versus ofatumumab. Blood 2019; .

    • Crossref
    • Export Citation
  • 60

    O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016; 17: 1409–1418.

  • 61

    Hallek M, Kay NE, Osterborg A, et al. The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11: 51–59.

  • 62

    Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016; 17: 200–211.

  • 63

    Fraser G, Cramer P, Demirkan F, et al. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia 2018; .

    • Crossref
    • Export Citation
  • 64

    Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20: 43–56.

  • 65

    Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018; 379: 2517–2528.

  • 66

    Shanafelt TD, Wang V, Kay NE, et al. A Randomized Phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912). Blood 2018; 132: LBA-4.

  • 67

    Collett L, Howard DR, Munir T, et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials 2017; 18: 387.

  • 68

    Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369: 507–516.

  • 69

    Gertz MA. Waldenström macroglobulinemia treatment algorithm 2018. Blood Cancer J. 2018; 8: 40.

  • 70

    Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017; 129: 2224–2232.

  • 71

    Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497–2506.

  • 72

    O’Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 2018; 131: 1910–1919.

  • 73

    Byrd JC, Furman RR, Coutre S, et al. Up to 7 years of follow-up of single-agent ibrutinib in the Phase 1b/2 PCYC-1102 trial of first line and relapsed/refractory patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. In: 60th American Society of Hematology Annual Meeting; December 1–4, 2018; San Diego, CA. Abstract 3133. http://ash.confex.com/ash/2018/webprogram/Paper110847.html.

  • 74

    Woyach JA. How I manage ibrutinib-refractory chronic lymphocytic leukemia. Blood 2017; 129: 1270–1274.

  • 75

    Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015; 1: 80–87.

  • 76

    Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood 2015; 125: 2062–2067.

  • 77

    Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018; 11: 185–194.

  • 78

    Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014; 370: 2286–2294.

  • 79

    Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood 2015; 126: 471–477.

  • 80

    Zhou Q, Lee GS, Brady J, et al. A hypermorphic missense mutation in PLCG2, encoding phospholipase Cγ2, causes a dominantly inherited autoinflammatory disease with immunodeficiency. Am J Hum Genet. 2012; 91: 713–720.

  • 81

    Walliser C, Hermkes E, Schade A, et al. The phospholipase Cgamma2 mutants R665W and L845F identified in ibrutinib-resistant chronic lymphocytic leukemia patients are hypersensitive to the Rho GTPase Rac2 protein. J Biol Chem. 2016; 291: 22136–22148.

  • 82

    Burger JA, Landau DA, Taylor-Weiner A, et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016; 7: 11589.

  • 83

    Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017; 35: 1437–1443.

  • 84

    Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481: 306–313.

  • 85

    Ahn IE, Underbayev C, Albitar A, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood 2017; 129: 1469–1479.

  • 86

    Komarova NL, Burger JA, Wodarz D. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proc Nat Acad Sci. U S A 2014; 111: 13906–13911.

  • 87

    Albitar A, Ma W, DeDios I, et al. Using high-sensitivity sequencing for the detection of mutations in BTK and PLCgamma2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors. Oncotarget. 2017; 8: 17936–17944.

  • 88

    Condoluci A, Rossi D. Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment. Expert Rev Hematol. 2019: 1–10.

  • 89

    Reiff SD, Muhowski EM, Guinn D, et al. Non-covalent inhibition of C481S Bruton’s tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib resistant CLL. Blood 2018; 132: 1039–1049.

  • 90

    Reiff SD, Mantel R, Smith LL, et al. The BTK inhibitor ARQ 531 targets ibrutinib-resistant CLL and Richter transformation. Cancer Discov. 2018; 8: 1300–1315.

  • 91

    Johnson AR, Kohli PB, Katewa A, et al. Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations. ACS Chemical Biology 2016; 11: 2897–2907.

  • 92

    Bottoni A, Rizzotto L, Lai T-H, et al. Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood 2016; 128: 3101–3112.

  • 93

    Kopp N, Tschuri S, Haebe S, et al. Newer-generation HSP90 inhibitors can overcome ibrutinib resistance and suppress proliferation in human mantle cell lymphoma in vitro and in vivo. Blood 2014; 124: 1686.

  • 94

    Hing ZA, Mantel R, Beckwith KA, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood 2015; 125: 3128–3132.

  • 95

    El-Gamal D, Williams K, LaFollette TD, et al. PKC-beta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood 2014; 124: 1481–1491.

  • 96

    Kuo HP, Crowley R, Xue L, et al. Combination of ibrutinib and BCL-2 or SYK inhibitors in ibrutinib resistant ABC-subtype of diffuse large B-cell lymphoma. Blood 2014; 124: 505.

  • 97

    Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017; 18: 297–311.

  • 98

    Lampson BL, Brown JR. PI3Kdelta-selective and PI3Kalpha/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 2017; 26: 1267–1279.

  • 99

    Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018; 19: 65–75.

  • 100

    Hillman P, Rawstron A, Brock K, et al. Ibrutinib plus venetoclax in relapsed/refractory CLL: results of the Bloodwise TAP Clarity Study. Presented at: 2018 ASH Annual Meeting; Dec. 1–4, 2018; San Diego, CA. Abstract 182.

  • 101

    Nitin J, et al. Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk chronic lymphocytic leukemia (CLL). Blood 2018; 132: 696; https://doi.org/10.1182/blood-‌2018-186.

  • Collapse
  • Expand
Cover Hematológia–Transzfuziológia
Hematológia–Transzfuziológia
Print ISSN:
1786-5913

 

  • Árpád ILLÉS (Debreceni Egyetem, főszerkesztő)
  • Csaba BÖDÖR (Semmelweis Egyetem, főszerkesztő-helyettes)
  • Judit DEMETER (Semmelweis Egyetem, főszerkesztő-helyettes)
  • Lajos GERGELY (Debreceni Egyetem, főszerkesztő-helyettes)
  • Imelda MARTON (Szegedi Tudományegyetem, főszerkesztő-helyettes)
  • Gábor MIKALA (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, főszerkesztő-helyettes)
  • Sándor FEKETE (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, emeritus főszerkesztő)
  • Hussain ALIZADEH (Pécsi Tudományegyetem, szerkesztő)
  • Hajnalka ANDRIKOVICS (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • Zita BORBÉNYI (Szegedi Tudományegyetem, szerkesztő)
  • Miklós EGYED (Somogy Megyei Kaposi Mór Oktató Kórház, szerkesztő)
  • Zsuzsanna FAUST (Pécsi Tudományegyetem, szerkesztő)
  • Béla KAJTÁR (Pécsi Tudományegyetem, szerkesztő)
  • Gergely KRIVÁN (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • András MASSZI (Országos Onkológiai Intézet, szerkesztő)
  • Tamás MASSZI (Semmelweis Egyetem, szerkesztő)
  • Zsolt György NAGY (Semmelweis Egyetem, szerkesztő)
  • Márk PLANDER (Vas Vármegyei Markusovszky Egyetemi Oktatókórház, szerkesztő)
  • György PFLIEGLER (Debreceni Egyetem, szerkesztő)
  • Péter REMÉNYI (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • Marienn RÉTI (Dél-Pesti Centrumkórház, Országos Hematológiai és Infektológiai Intézet, szerkesztő)
  • János SINKÓ (Semmelweis Egyetem, szerkesztő)
  • László SZERAFIN (Szabolcs-Szatmár-Bereg Megyei Jósa András Oktatókórház, Nyíregyháza, szerkesztő)

Hematológia-Transzfuziológia Szerkesztőség
Dr. Illés Árpád
Debreceni Egyetem Klinikai Központ
Belgyógyászati Intézet B épület
4012 Debrecen, Nagyerdei krt. 98. Pf.: 20.
E-mail: illesarpaddr@gmail.com

  • CABELLS Journalytics

Hematológia-Transzfuziológia
Publication Model Hybrid
Submission Fee none
Article Processing Charge 900 EUR/article
Regional discounts on country of the funding agency World Bank Lower-middle-income economies: 50%
World Bank Low-income economies: 100%
Further Discounts Editorial Board / Advisory Board members: 50%
Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100%
Subscription fee 2025 Online subsscription: 100 EUR / 110 USD
Print + online subscription: 112 EUR / 124 USD
Subscription Information Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content.
Purchase per Title Individual articles are sold on the displayed price.

Hematológia-Transzfuziológia
Language Hungarian
Size A4
Year of
Foundation		 2004
Volumes
per Year		 1
Issues
per Year		 4
Founder Magyar Hematológiai és Transzfuziológiai Társaság
Founder's
Address		 Szent László Kórház, Hematológiai Osztály H-1097 Budapest, Hungary Gyáli út 5-7.
Publisher Akadémiai Kiadó
Publisher's
Address		 H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher		 Chief Executive Officer, Akadémiai Kiadó
ISSN 1786-5913 (Print)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Oct 2024 0 112 20
Nov 2024 0 194 69
Dec 2024 0 239 47
Jan 2025 0 98 44
Feb 2025 0 149 57
Mar 2025 0 163 50
Apr 2025 0 0 0